Article PDF
References
Koff AB, Rosen T. Treatment of mucocutaneous leishmaniasis. J Am Acad Dermatol 1994; 31 (5 Pt 1): 693–708
Bhadra R. Antileishmanial agents. Drug Fut 1993; 18: 451–63
Ho JL, Hatzigeorgiou D, Reed SG, et al. Cytokines in the treatment of leishmaniasis: from studies of immunopathology to patient therapy. Biotherapy 1994; 7: 223–35
Martindale. The Extra Pharmacopoeia, 30th ed. London; The Pharmaceutical Press, 1993; 509–27
Lockwood DNJ, Pas vol G. Recent advances in tropical medicine. BMJ 1994; 308: 1559–62
Herwaldt BL, Berman JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am J Trop Med 1992; 46: 296–306
Jernigan JA, Pearson RD. Chemotherapy of leishmaniasis, Chagas’ disease and African trypanosomiasis. Curr Opin Infect Dis 1993; 6: 794–802
Cook GC. Leishmaniasis: some recent developments in chemotherapy. J Antimicrob Chemother 1993; 31: 327–30
Soto-Mancipe J, Grogl M, Berman JD. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 1993; 16: 417–25
Mishra M, Biswas UK, Jha AM, et al. Amphotericin versus sodium stibogluconate in first-line treatment of Indian kala-azar. Lancet 1994; 344: 1599–600
Mishra M, Biswas UK, Jha AM, et al. Amphotericin versus pentamidine in antimony-unresponsive kala-azar. Lancet 1992; 340: 1256–7
Targeting drugs using liposomes: new drugs from old. Drug Ther Perspect 1993 Mar 8; 1(4): 13–15
Dietze R, Milan EP, Berman JD, et al. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion). Clin Infect Dis 1993; 17: 981–6
Davidson RN, Di Martino L, Gradoni L, et al. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: a multi-centre trial. Q J Med 1994; 87: 75–81
Wali JP, Aggarwal P, Gupta U, et al. Ketoconazole in the treatment of antimony-and pentamidine-resistant kala-azar [letter]. J Infect Dis 1992; 166: 215–6
Wali JP, Aggarwal P, Gupta U, et al. Ketoconazole in the treatment of visceral leishmaniasis [letter]. Lancet 1990; 336: 810–1
Sundar S, Kumar K, Singh VP. Ketoconazole in visceral leishmaniasis [letter]. Lancet 1990; 336: 1582–3
Navin TR, Arana BA, Arana FE, et al. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J Infect Dis 1992; 165: 528–34
Saenz RE, Paz H, Berman JD. Efficacy of ketoconazole against Leishmania braziliensis panamensis cutaneous leishmaniasis. Am J Med 1990; 89: 147–55
Akuffo H, Dietz M, Teklemariam S, et al. The use of itraconazole in the treatment of leishmaniasis caused by Leishmania aethiopica. Trans R Soc Trop Med Hyg 1990; 84: 532–4
Al-Fouzan AS, Al Saleh QA, Narem NM, et al. Cutaneous leishmaniasis in Kuwait. Int J Dermatol 1991; 30: 519–21
Dogra J, Aneja N, Behari B, et al. Cutaneous leishmaniasis in India. Int J Dermatol 1990; 29: 661–2
Day RO, Birkett DJ, Hicks M, et al. New uses for allopurinol. Drugs 1994; 48: 339–44
Martinez S, Marr JJ. Allopurinol in the treatment of american cutaneous leishmaniasis. N Engl J Med 1992; 326: 741–4
Saenz RE, Paz HM, Johnson CM, et al. Treatment of American cutaneous leishmaniasis with orally administered allopurinol riboside. J Infect Dis 1989; 160: 153–8
Ragusa R, Di Cataldo A, Samperi P, et al. Treatment of visceral leishmaniasis with meglumine and allopurinol [letter]. Am J Dis Child 1993; 147: 611–2
di Martino L, Pettoello Mantovani M, Gradoni L, et al. Low dosage combination of meglumine antimoniate plus allopurinol as first choice treatment of infantile visceral leishmaniasis in Italy. Trans R Soc Trop Med Hyg 1990; 84: 534–5
Laguna F, Lopez-Vélez R, Soriano V, et al. Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. J Infect 1994; 28: 255–9
Playfair JHL, Blackwell JM, Miller HRP. Parasitic diseases. Lancet 1990; 335: 1263–6
Convit J, Rondon A, Ulrich M, et al. Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet 1987 Feb 21; 1: 401–4
Nascimento E, Mayrink W, Dacosta CA, et al. Vaccination of humans against cutaneous leishmaniasis: cellular and humoral responses. Infect Immun 1990; 58: 2198–2203
Rights and permissions
About this article
Cite this article
Leishmaniasis: pentavalent antimonials still primary therapy. Drugs Ther. Perspect 5, 11–14 (1995). https://doi.org/10.2165/00042310-199505060-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199505060-00005